{"id":32778,"date":"2025-04-30T21:27:09","date_gmt":"2025-04-30T13:27:09","guid":{"rendered":"https:\/\/flcube.com\/?p=32778"},"modified":"2025-04-30T21:27:11","modified_gmt":"2025-04-30T13:27:11","slug":"eli-lilly-partners-with-creyon-bio-to-develop-rna-targeted-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32778","title":{"rendered":"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies"},"content":{"rendered":"\n

Eli Lilly and Company (NYSE: LLY<\/a>) announced a strategic collaboration with Creyon Bio, Inc., a U.S.-based AI drug discovery innovator, to co-develop RNA-targeted oligonucleotide therapies for multiple disease targets. This partnership aims to leverage Creyon’s proprietary Oligo Engineering Engine, an AI-powered platform that enables ultra-rapid design and optimization of nucleic acid drugs with cycle times 10x faster than conventional methods.<\/p>\n\n\n\n

Financial Terms and Partnership Structure<\/strong>
Under the deal, Creyon will receive a USD 13 million upfront payment, including cash and the purchase of Creyon equity. Additionally, Creyon is eligible to receive over USD 1 billion in development and commercialization milestone payments. Eli Lilly secures an exclusive license to lead candidates for each target and assumes full responsibility for clinical development and global commercialization moving forward.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a…<\/p>\n","protected":false},"author":1,"featured_media":32781,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4043,199,911,64],"class_list":["post-32778","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-creyon-bio","tag-eli-lilly","tag-nyse-lly","tag-rnai-aso"],"yoast_head":"\nEli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a U.S.-based AI drug discovery innovator, to co-develop RNA-targeted oligonucleotide therapies for multiple disease targets. This partnership aims to leverage Creyon\u2019s proprietary Oligo Engineering Engine, an AI-powered platform that enables ultra-rapid design and optimization of nucleic acid drugs with cycle times 10x faster than conventional methods.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32778\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a U.S.-based AI drug discovery innovator, to co-develop RNA-targeted oligonucleotide therapies for multiple disease targets. This partnership aims to leverage Creyon\u2019s proprietary Oligo Engineering Engine, an AI-powered platform that enables ultra-rapid design and optimization of nucleic acid drugs with cycle times 10x faster than conventional methods.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32778\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-30T13:27:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-30T13:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3013.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32778#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32778\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies\",\"datePublished\":\"2025-04-30T13:27:09+00:00\",\"dateModified\":\"2025-04-30T13:27:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32778\"},\"wordCount\":140,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32778#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3013.webp\",\"keywords\":[\"Creyon Bio\",\"Eli Lilly\",\"NYSE: LLY\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32778#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32778\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32778\",\"name\":\"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32778#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32778#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3013.webp\",\"datePublished\":\"2025-04-30T13:27:09+00:00\",\"dateModified\":\"2025-04-30T13:27:11+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a U.S.-based AI drug discovery innovator, to co-develop RNA-targeted oligonucleotide therapies for multiple disease targets. This partnership aims to leverage Creyon\u2019s proprietary Oligo Engineering Engine, an AI-powered platform that enables ultra-rapid design and optimization of nucleic acid drugs with cycle times 10x faster than conventional methods.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32778#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32778\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32778#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3013.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3013.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32778#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies - Insight, China's Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a U.S.-based AI drug discovery innovator, to co-develop RNA-targeted oligonucleotide therapies for multiple disease targets. This partnership aims to leverage Creyon\u2019s proprietary Oligo Engineering Engine, an AI-powered platform that enables ultra-rapid design and optimization of nucleic acid drugs with cycle times 10x faster than conventional methods.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32778","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies","og_description":"Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a U.S.-based AI drug discovery innovator, to co-develop RNA-targeted oligonucleotide therapies for multiple disease targets. This partnership aims to leverage Creyon\u2019s proprietary Oligo Engineering Engine, an AI-powered platform that enables ultra-rapid design and optimization of nucleic acid drugs with cycle times 10x faster than conventional methods.","og_url":"https:\/\/flcube.com\/?p=32778","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-30T13:27:09+00:00","article_modified_time":"2025-04-30T13:27:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3013.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32778#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32778"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies","datePublished":"2025-04-30T13:27:09+00:00","dateModified":"2025-04-30T13:27:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32778"},"wordCount":140,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32778#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3013.webp","keywords":["Creyon Bio","Eli Lilly","NYSE: LLY","RNAi \/ ASO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32778#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32778","url":"https:\/\/flcube.com\/?p=32778","name":"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32778#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32778#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3013.webp","datePublished":"2025-04-30T13:27:09+00:00","dateModified":"2025-04-30T13:27:11+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a U.S.-based AI drug discovery innovator, to co-develop RNA-targeted oligonucleotide therapies for multiple disease targets. This partnership aims to leverage Creyon\u2019s proprietary Oligo Engineering Engine, an AI-powered platform that enables ultra-rapid design and optimization of nucleic acid drugs with cycle times 10x faster than conventional methods.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32778#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32778"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32778#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3013.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3013.webp","width":1080,"height":608,"caption":"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32778#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3013.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32778"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32778\/revisions"}],"predecessor-version":[{"id":32782,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32778\/revisions\/32782"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32781"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}